FDA approves Endo’s Qwo for treatment of cellulite

Endo International (NASDAQ:ENDP) has received FDA approval of QWO (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women. This is the first FDA-approved injectable treatment for cellulite.

QWO is expected to be available throughout the U.S. in Spring 2021.

https://seekingalpha.com/news/3588978-fda-approves-endos-qwo-for-treatment-of-cellulite